SEC 13F Intelligence

Managers / Q1 2026

Birchview Capital, LP

CIK 0001618205 · 688 PINE STREET, SUITE D, C/O BIRCHVIEW CAPITAL, BURLINGTON, VT, 05401 · 802-923-3826

Reported Value
$176M
Q1 2026
Positions
73
Filings on Record
39
2019–present window
Filed
May 15, 2026
original filing

Summary

Birchview Capital, LP reported $176M in U.S.-listed holdings across 73 positions for Q1 2026.

Its largest position, KLAC, represents 16.7% of the portfolio.

Compared with Q4 2025, the fund opened 17 new positions and exited 12.

Portfolio Metrics

Turnover
+19.1%
vs prior filed quarter
Top-10 Concentration
+54.6%
share of reported value
Largest Position
+16.7%
Kla Corporation
New / Exited
17 / 12
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $106MQ4 ’18Q1 ’19: $160MQ2 ’19: $164MQ3 ’19: $150MQ4 ’19: $138MQ4 ’19Q1 ’20: $113MQ2 ’20: $165MQ3 ’20: $150MQ4 ’20: $174MQ4 ’20Q1 ’21: $168MQ2 ’21: $167MQ3 ’21: $147MQ4 ’21: $155MQ4 ’21Q1 ’22: $139MQ2 ’22: $137MQ3 ’22: $142MQ1 ’23: $127,725Q1 ’23Q3 ’23: $117MQ4 ’23: $128MQ1 ’24: $122MQ2 ’24: $108MQ2 ’24Q3 ’24: $115MQ4 ’24: $123MQ1 ’25: $115MQ2 ’25: $101MQ2 ’25Q3 ’25: $132MQ4 ’25: $171MQ1 ’26: $176Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 85.3%Other: 9.5%ADR: 5.2%
  • Common Stock · 85.3% · $150M
  • Other · 9.5% · $17M
  • ADR · 5.2% · $9M

Quarter-over-Quarter Changes full breakdown →

vs Q4 2025 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
RLMDRELMADA THERAPEUTICS INCNEW+409.4K409.4K+$3M$3M
OCULOCULAR THERAPEUTIX INCNEW+320.0K320.0K+$3M$3M
TCE2CELLDEX THERAPEUTICS INCNEW+70.1K70.1K+$2M$2M
CMPSCOMPASS PATHWAYS LTDNEW+375.0K375.0K+$2M$2M
ENGENE HOLDINGS INCNEW+250.0K250.0K+$2M$2M
ZBIOZENAS BIOPHARMA INCNEW+70.0K70.0K+$1M$1M
BIIBBIOGEN INCNEW+5.0K5.0K+$916,650$916,650
LPCNLIPOCINE INCNEW+111.8K111.8K+$893,170$893,170

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q1 2026

50 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1KLACKLA CORPORATIONhistory →COM NEW16.67%$29M19.9K
2BMYBRISTOL-MYERS SQUIBB COhistory →COM10.57%$19M306.3K
3CMPXCOMPASS THERAPEUTICS INChistory →COM4.41%$8M1.47M
4LRCXLAM RESEARCH CORPORATIONhistory →COM NEW4.38%$8M36.0K
5STOKSTOKE THERAPEUTICS INChistory →COM3.89%$7M210.0K
6OVVOVINTIV INChistory →COM3.63%$6M107.5K
7NTLAINTELLIA THERAPEUTICS INChistory →COM3.25%$6M445.4K
8GPCRSTRUCTURE THERAPEUTICS INChistory →SPONS ADR2.74%$5M100.0K
9SLDBSOLID BIOSCIENCES INChistory →COM NEW2.57%$5M626.0K
10PROTHENA CORP PLCSHS2.48%$4M449.0K
11BIODESIX INCCOM2.37%$4M286.8K
12ACADACADIA PHARMACEUTICALS INChistory →COM2.17%$4M171.0K
13PTGXPROTAGONIST THERAPEUTICS INChistory →COM2.10%$4M35.0K
14NBIXNEUROCRINE BIOSCIENCES INChistory →COM2.04%$4M27.2K
15OLMAOLEMA PHARMACEUTICALS INChistory →COM1.86%$3M219.0K
16RLMDRELMADA THERAPEUTICS INChistory →COM1.62%$3M409.4K
17OCULOCULAR THERAPEUTIX INChistory →COM1.54%$3M320.0K
18UTHUNITED THERAPEUTICS CORPhistory →COM1.52%$3M4.5K
19NKTRNEKTAR THERAPEUTICShistory →COM1.27%$2M31.0K
20TCE2CELLDEX THERAPEUTICS INChistory →COM NEW1.27%$2M70.1K
21NOVOCURE LTDORD SHS1.26%$2M202.3K
22EQTEQT CORPORATIONhistory →COM1.25%$2M34.6K
23PHATPHATHOM PHARMACEUTICALS INChistory →COM1.23%$2M195.0K
24BCYCBICYCLE THERAPEUTICS PLChistory →SPONSORED ADS1.22%$2M463.6K
25CMPSCOMPASS PATHWAYS LTDhistory →SPONSORED ADS1.18%$2M375.0K
26PACBPACIFIC BIOSCIENCES OF CALIFORNIA INChistory →COM1.13%$2M1.50M
27CYTKCYTOKINETICS INChistory →COM1.13%$2M30.0K
28HTDCORCEPT THERAPEUTICS INChistory →COM1.08%$2M47.2K
29VERAVERA THERAPEUTICS INChistory →CL A1.01%$2M44.0K
30ALKERMES PLCSHS1.01%$2M50.0K
31ENGENE HOLDINGS INCCOM0.97%$2M250.0K
32UNIQURE NVSHS0.94%$2M100.7K
33ZBIOZENAS BIOPHARMA INCCOM0.78%$1M70.0K
34QDEL*QUIDELORTHO CORPCOM0.77%$1M82.5K
35FHTXFOGHORN THERAPEUTICS INCCOM0.77%$1M281.7K
36RAREULTRAGENYX PHARMACEUTICAL INCCOM0.74%$1M62.0K
37XENEXENON PHARMACEUTICALS INCCOM0.70%$1M21.0K
384XC1KALVISTA PHARMACEUTICALS INCCOM0.65%$1M57.0K
39IMNMIMMUNOME INCCOM0.62%$1M50.0K
40FCXFREEPORT-MCMORAN CL-BCL-B0.60%$1M18.0K
41AXSMAXSOME THERAPEUTICS INCCOM0.58%$1M6.0K
42BIIBBIOGEN INCCOM0.52%$916,6505.0K
43LPCNLIPOCINE INCCOM NEW0.51%$893,170111.8K
44TVTXTRAVERE THERAPEUTICS INCCOM0.49%$867,53229.2K
45HROWHARROW HEALTH INCCOM0.48%$846,24024.0K
46PHARVARIS N VCOM0.48%$843,17829.8K
47VSTMVERASTEM INCCOM NEW0.45%$795,000150.0K
48APGEAPOGEE THERAPEUTICS INCCOM0.43%$757,5309.0K
49HALOHALOZYME THERAPEUTICS INCCOM0.37%$652,76310.1K
50BBIOBRIDGEBIO PHARMA INCCOM0.37%$645,1718.7K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$176M73May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$171M68Feb 13, 202613F-HRchanges · EDGAR ↗
Q3 2025$132M69Nov 13, 202513F-HRchanges · EDGAR ↗
Q2 2025$101M71Aug 14, 202513F-HRchanges · EDGAR ↗
Q1 2025$115M68May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$123M68Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$115M62Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$108M61Aug 13, 202413F-HRchanges · EDGAR ↗
Q1 2024$122M60May 14, 202413F-HRchanges · EDGAR ↗
Q4 2023$128M59Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$117M52Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023Under review54Aug 8, 202313F-HRchanges · EDGAR ↗
Q1 2023$127,72555May 12, 202313F-HRchanges · EDGAR ↗
Q4 2022Under review57Feb 3, 202313F-HRchanges · EDGAR ↗
Q3 2022$142M60Nov 28, 2022RESTATEMENTchanges · EDGAR ↗
Q2 2022$137M64Aug 12, 202213F-HRchanges · EDGAR ↗
Q1 2022$139M63May 13, 202213F-HRchanges · EDGAR ↗
Q4 2021$155M67Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$147M64Nov 12, 202113F-HRchanges · EDGAR ↗
Q2 2021$167M62Aug 10, 202113F-HRchanges · EDGAR ↗
Q1 2021$168M54May 14, 202113F-HRchanges · EDGAR ↗
Q4 2020$174M48Feb 9, 202113F-HRchanges · EDGAR ↗
Q3 2020$150M50Nov 12, 2020RESTATEMENTchanges · EDGAR ↗
Q2 2020$165M51Aug 10, 202013F-HRchanges · EDGAR ↗
Q1 2020$113M46May 12, 202013F-HRchanges · EDGAR ↗
Q4 2019$138M52Feb 12, 202013F-HRchanges · EDGAR ↗
Q3 2019$150M50Nov 12, 201913F-HRchanges · EDGAR ↗
Q2 2019$164M54Aug 6, 201913F-HRchanges · EDGAR ↗
Q1 2019$160M54May 3, 201913F-HRchanges · EDGAR ↗
Q4 2018$106M52Feb 6, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.